Dapagliflozin reduces the amplitude of shortening and Ca2+ transient in ventricular myocytes from streptozotocin-induced diabetic rats

Molecular and Cellular Biochemistry

Volumn 400, Issue 1-2, 2015, Pages 57-68

  Hamouda, N N ^a   Sydorenko, V ^b   Qureshi, M A ^a   Alkaabi, J M ^a   Oz, M ^a   Howarth, F C ^a  

^a UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^b BOGOMOLETZ INSTITUTE OF PHYSIOLOGY   (Ukraine)

Author keywords

Dapagliflozin; Diabetes mellitus; SGLT2 inhibitors; Streptozotocin induced diabetic rats; Ventricular myocytes

Indexed keywords

CALCIUM; DAPAGLIFLOZIN; STREPTOZOCIN; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; BENZHYDRYL DERIVATIVE; GLUCOSE; GLUCOSE BLOOD LEVEL; GLUCOSIDE;

ANIMAL EXPERIMENT; ARTICLE; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CONTROLLED STUDY; ELECTROSTIMULATION; GLUCOSE BLOOD LEVEL; HEART MUSCLE CELL; INOTROPISM; MALE; MYOFILAMENT; NONHUMAN; PHOTOMETRY; RAT; SARCOPLASMIC RETICULUM; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; VIDEORECORDING; WHOLE CELL PATCH CLAMP; ANIMAL; DIABETES MELLITUS, EXPERIMENTAL; DRUG EFFECTS; HEART VENTRICLE; HUMAN; METABOLISM; PATCH CLAMP TECHNIQUE; PATHOLOGY;

ANIMALS; BENZHYDRYL COMPOUNDS; BLOOD GLUCOSE; CALCIUM; DIABETES MELLITUS, EXPERIMENTAL; GLUCOSE; GLUCOSIDES; HEART VENTRICLES; HUMANS; MYOCYTES, CARDIAC; PATCH-CLAMP TECHNIQUES; RATS; STREPTOZOCIN;

EID: 84922005208     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-014-2262-5     Document Type: Article

References (40)

1. International Diabetes Federation (2013) ATLAS. 6th ed. Brussels, Belgium
2. Malik M, Bakir A, Saab BA, King H (2005) Glucose intolerance and associated factors in the multi-ethnic population of the United Arab Emirates: results of a national survey. Diabetes Res Clin Pract 69(2):188–195
3. Brownie S, Hunter L, Rossiter R, Hills AP, Robb W, Hag-Ali M (2014) Diabetes in the United Arab Emirates: the need for valid datasets for health service planning. Lancet Diabetes Endocrinol 14:70025–70027
4. Vaccaro O, Eberly LE, Neaton JD, Yang L, Riccardi G, Stamler J (2004) Impact of diabetes and previous myocardial infarction on long-term survival: 25-year mortality follow-up of primary screenees of the multiple risk factor intervention trial. Arch Intern Med 164(13):1438–1443
5. Julien J (1997) Cardiac complications in non-insulin-dependent diabetes mellitus. J Diabetes Complicat 11:123–130
6. Bakth S, Arena J, Lee W, Torres R, Haider B, Patel BC, Lyons MM, Regan TJ (1986) Arrhythmia susceptibility and myocardial composition in diabetes. Influence of physical conditioning. J Clin Investig 77(2):382–395
7. Ewing DJ, Boland O, Neilson JM, Cho CG, Clarke BF (1991) Autonomic neuropathy, QT interval lengthening, and unexpected deaths in male diabetic patients. Diabetologia 34(3):182–185
8. Grimm W, Langenfeld H, Maisch B, Kochsiek K (1990) Symptoms, cardiovascular risk profile and spontaneous ECG in paced patients: a five-year follow-up study. Pacing Clin Electrophysiol 13(12 Pt 2):2086–2090
9. Movahed MR, Hashemzadeh M, Jamal MM (2005) Increased prevalence of third-degree atrioventricular block in patients with type II diabetes mellitus. Chest 128(4):2611–2614
10. Fallow GD, Singh J (2004) The prevalence, type and severity of cardiovascular disease in diabetic and non-diabetic patients: a matched-paired retrospective analysis using coronary angiography as the diagnostic tool. Mol Cell Biochem 261(1–2):263–269
11. Chen J, Williams S, Ho S, Loraine H, Hagan D, Whaley JM, Feder JN (2010) Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members. Diabetes Ther 1(2):57–92
12. Banerjee SK, McGaffin KR, Pastor-Soler NM, Ahmad F (2009) SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states. Cardiovasc Res 84(1):111–118
13. Abdul-Ghani MA, Norton L, Defronzo RA (2011) Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev 32(4):515–531
14. Clar C, Gill JA, Court R, Waugh N (2012) Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes. BMJ Open 2(5):e001007
15. Musso G, Gambino R, Cassader M, Pagano G (2012) A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. Ann Med 44(4):375–393
16. Stenlof K, Cefalu WT, Kim KA, Alba M, Usiskin K, Tong C, Canovatchel W, Meininger G (2013) Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 15(4):372–382
17. FDA Approves Invokana to treat type 2 diabetes. (2013) Food and Drug Administration
18. Meng W, Ellsworth BA, Nirschl AA, McCann PJ, Patel M, Girotra RN, Wu G, Sher PM, Morrison EP, Biller SA, Zahler R, Deshpande PP, Pullockaran A, Hagan DL, Morgan N, Taylor JR, Obermeier MT, Humphreys WG, Khanna A, Discenza L, Robertson JG, Wang A, Han S, Wetterau JR, Janovitz EB, Flint OP, Whaley JM, Washburn WN (2008) Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem 51(5):1145–1149
19. Foote C, Perkovic V, Neal B (2012) Effects of SGLT2 inhibitors on cardiovascular outcomes. Diabetes Vasc Dis Res 9(2):117–123
20. Carlson GF, Tou CK, Parikh S, Birmingham BK, Butler K (2011) Evaluation of the effect of dapagliflozin on cardiac repolarization: a thorough QT/QTc study. Diabetes Ther 2(3):123–132
21. Howarth FC, Qureshi MA, White E (2002) Effects of hyperosmotic shrinking on ventricular myocyte shortening and intracellular Ca(2+) in streptozotocin-induced diabetic rats. Pflügers Arch 444(3):446–451
22. Isenberg G, Klockner U (1982) Calcium tolerant ventricular myocytes prepared by preincubation in a “KB medium”. Pflügers Arch 395(1):6–18
23. Zhao Y, Xu J, Gong J, Qian L (2009) L-type calcium channel current up-regulation by chronic stress is associated with increased alpha(1c) subunit expression in rat ventricular myocytes. Cell Stress Chaperones 14(1):33–41
24. Kerfant BG, Vassort G, Gomez AM (2001) Microtubule disruption by colchicine reversibly enhances calcium signaling in intact rat cardiac myocytes. Circ Res 88(7):E59–E65
25. Sun Q, Ma Y, Zhang L, Zhao YF, Zang WJ, Chen C (2010) Effects of GH secretagogues on contractility and Ca2+ homeostasis of isolated adult rat ventricular myocytes. Endocrinology 151(9):4446–4454
26. Howarth FC, Qureshi MA, Sobhy ZH, Parekh K, Yammahi SR, Adrian TE, Adeghate E (2011) Structural lesions and changing pattern of expression of genes encoding cardiac muscle proteins are associated with ventricular myocyte dysfunction in type 2 diabetic Goto-Kakizaki rats fed a high-fat diet. Exp Physiol 96(8):765–777
27. Howarth FC, Qureshi MA (2008) Myofilament sensitivity to Ca2+ in ventricular myocytes from the Goto-Kakizaki diabetic rat. Mol Cell Biochem 315(1–2):69–74
28. Spurgeon HA, DuBell WH, Stern MD, Sollott SJ, Ziman BD, Silverman HS, Capogrossi MC, Talo A, Lakatta EG (1992) Cytosolic calcium and myofilaments in single rat cardiac myocytes achieve a dynamic equilibrium during twitch relaxation. J Physiol 447:83–102:83–102
29. Bassani JW, Yuan WL, Bers DM (1995) Fractional SR Ca release is regulated by trigger Ca and SR Ca content in cardiac myocytes. Am J Physiol 37:C1313–C1319
30. Howarth FC, Calaghan SC, Boyett MR, White E (1999) Effect of the microtubule polymerizing agent taxol on contraction, Ca2+ transient and L-type Ca2+ current in rat ventricular myocytes. J Physiol 516(Pt 2):409–419
31. Levi AJ, Hancox JC, Howarth FC, Croker J, Vinnicombe J (1996) A method for making rapid changes of superfusate whilst maintaining temperature at 37 degrees C. Pflügers Arch 432(5):930–937
32. Salem KA, Qureshi MA, Sydorenko V, Parekh K, Jayaprakash P, Iqbal T, Singh J, Oz M, Adrian TE, Howarth FC (2013) Effects of exercise training on excitation-contraction coupling and related mRNA expression in hearts of Goto-Kakizaki type 2 diabetic rats. Mol Cell Biochem 380(1–2):83–96
33. von Lewinski D, Rainer PP, Gasser R, Huber MS, Khafaga M, Wilhelm B, Haas T, Machler H, Rossl U, Pieske B (2010) Glucose-transporter-mediated positive inotropic effects in human myocardium of diabetic and nondiabetic patients. Metabolism 59(7):1020–1028
34. Zhou L, Cryan EV, D’Andrea MR, Belkowski S, Conway BR, Demarest KT (2003) Human cardiomyocytes express high level of Na+/glucose cotransporter 1 (SGLT1). J Cell Biochem 90(2):339–346
35. von Lewinski D, Gasser R, Rainer PP, Huber MS, Wilhelm B, Roessl U, Haas T, Wasler A, Grimm M, Bisping E, Pieske B (2010) Functional effects of glucose transporters in human ventricular myocardium. Eur J Heart Fail 12(2):106–113
36. Bracken N, Howarth FC, Singh J (2006) Effects of streptozotocin-induced diabetes on contraction and calcium transport in rat ventricular cardiomyocytes. Ann NY Acad Sci 1084:208–222
37. Bracken NK, Woodall AJ, Howarth FC, Singh J (2004) Voltage-dependence of contraction in streptozotocin-induced diabetic myocytes. Mol Cell Biochem 261(1–2):235–243
38. Bean BP (1984) Nitrendipine block of cardiac calcium channels: high-affinity binding to the inactivated state. Proc Natl Acad Sci USA 81:6388–6392
39. Hering S, Aczel S, Kraus RL, Berjukow S, Striessnig J, Timin EN (1997) Molecular mechanism of use-dependent calcium channel block by phenylalkylamines: role of inactivation. Proc Natl Acad Sci USA 94(24):13323–13328
40. Hess P, Lansman JB, Tsien RW (1983) Different modes of Ca channel gating behaviour favoured by dihydropyridine Ca agonists and antagonists. Nature 311:538–544